Illumina

Director - General Manager, Canada

British Columbia, Canada

Auto‑apply with AI Apply

$250,000 – $350,000Compensation

Senior (5 to 8 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Life Sciences, HealthcareIndustries

Requirements

Candidates should possess strategic leadership skills, experience in driving business success, an understanding of the genomics market, and the ability to lead and manage teams.

Responsibilities

The Director - General Manager, Canada will lead the Canada business through a team of direct customer-facing functions, aligning and leveraging execution resources to maximize market adoption and success, and attaining financial and strategic goals for the business within the geography. This role involves driving accelerated revenue growth and market penetration in both life sciences and clinical market businesses, leading the genomics ecosystem within the region, and developing the country/region’s go-to-market strategy in partnership with marketing and forecasts.

Skills

Strategic Leadership

Business Development

Genomics Market

Team Management

Revenue Growth

Market Penetration

Go-to-Market Strategy

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

Key Metrics

San Diego, CaliforniaHeadquarters

1998Year Founded

$27.2MTotal Funding

IPOCompany Stage

Venture Capital, BiotechnologyIndustries

5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.

Standardizing proteomics data across platforms could challenge Illumina's data reliability.

Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.

The company offers innovative array-based solutions for DNA, RNA, and protein analysis.

Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.

Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.

Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI

Try Jobo Free